Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 PK, safety and tolerability of naldemedine in paediatric patients on opioids
jRCT2031250151Phase 2Recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of naldemedine in opioid-induced constipation (OIC), sponsored by Shionogi & Co., Ltd. Primary endpoint: Pharmacokinetics parameters. Started Jun 2025; status: recruiting.
02
Drugs
naldemedine
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on jRCT2031250151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250151.